Back to Authors

Dodick, David W.

https://orcid.org/0000-0002-9486-6790

A5057290642 | I1330342723

Mayo Clinic

Atria Academy of Science and Medicine, New York, NY, United States

Citations 387

Atogepant Improved Patient-Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine (1454)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1454

Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data from a Phase 3 Clinical Trial (ADVANCE) in Patients with Episodic Migraine (1431)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1431

Improved Functionality, Satisfaction, and Global Impression of Change With Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders (1247)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1247

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) (870)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.870

Sensory Hypersensitivity Symptoms in Migraine with vs. Without Aura: Results from the American Registry for Migraine Research (ARMR) (83)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.83

Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2 (617)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.617

Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2 (541)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.541

Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication (533)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.533

Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study (502)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.502

Ubrogepant is Effective in the Acute Treatment of Migraine with Mild Pain (4726)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4726